PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility - Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide unveils new facility
Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility

 

NewswireToday - /newswire/ - Cambridgeshire, United Kingdom, 2010/09/14 - Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide unveils new facility.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Quotient Bioresearch has officially opened its new, state-of-the-art radiochemistry facility in Cardiff, UK, with a ceremony including a VIP opening by the First Minister of Wales, Carwyn Jones.

The new facility, which has been named “The Old Glassworks”, represents a £15 Million investment for Quotient, which was assisted by International Business Wales, the inward investment arm of the Welsh Assembly Government. The Old Glassworks produces radiolabelled compounds, enabling Quotient to support the product development needs of the pharmaceutical, biotechnology and agrochemicals industries worldwide. From the new facility, Quotient is able to manufacture custom radiolabelled drugs for use in both pre-clinical and clinical settings, serving over 250 clients worldwide.

The Old Glassworks houses the largest and most experienced team of radiosynthesis chemists in the world and has already created approximately 25 new jobs, bringing the total number of Quotient employees to over 600. The new facility follows the company’s acquisition of Amersham Radiolabeling Services from GE Healthcare in June 2009 and has enabled seventy-five highly-skilled chemists and support staff to be transferred.

The official ceremony included a VIP opening and unveiling of a plaque by the First Minister of Wales, as well as a speech by Stephen Lewinton, Managing Director for Chemistry and Metabolism at Quotient Bioresearch. Presentations were given by company executives and scientists, discussing the challenges involved in building the new facility, and recommendations for effective experimental design. Guests were also given tours of the facility to view Quotient’s world-class technology.

Paul Cowan, Chairman & Chief Executive Officer, Quotient Bioresearch, said: “We are delighted to announce the official opening of Quotient’s new state-of-the-art facility in Cardiff, Wales. The new facility, which is equipped with world-leading technology, will enable Quotient to offer a bespoke service for the custom synthesis of carbon-14 and tritium labelled compounds.”

Carwyn Jones, First Minister of Wales, said “The Cardiff facility is a centre of excellence for the manufacture of radiolabelled compounds to support Quotient’s pharmaceutical and biotechnology client’s ongoing research and development programmes. The use of radiolabelled compounds is critical to evaluating the safety of new medicines being developed to benefit people with a wide range of illnesses, in both the UK and the rest of the world.”

To learn more about the new facility or Quotient, please call +44 (0)2920 474 900, email info.amersham[.]quotientbioresearch.com

About Quotient Bioresearch
Quotient (quotientbioresearch.com) is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide. The company offers a unique range of drug development services through its three key focus areas – Chemistry & Metabolism, Bioanalytical Sciences and Clinical Services. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioresearch Group, which comprises Quotient Bioresearch and HFL Sport Science.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sarah Evans - Scottpr.com 
+44 1477 539539 quotient[.]scottpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)